Search
Menu
Home
HTB
2012
August
HTB
August 2012
Contents
Editorial
Volume 13 Number 7/8 July/August 2012
Special reports
AIDS 2012: non-technical conference summaries: HTB supplement
Supplements
HIV and your quality of life: a guide to side effects and other complications (July 2012)
i-Base/TAG 2012 pipeline report
Conference reports
19th IAS World AIDS Conference, 22–25 July 2012, Washington
IAS: social and political talks online as web casts
New booster – cobicistat as an alternative to ritonavir
Dolutegravir vs raltegravir in treatment-naive patients: 48 week results from the SPRING 2 study
Elvitegravir vs raltegravir: 96 week phase III results in treatment experienced patients
In vitro and animal data support safety profile BMS 986001: d4T-like NRTI currently in clinical trials
Switching to rilpivirine/tenofovir/FTC fixed dose combination from boosted-PI regimen: SPIRIT study draws the line at 24 weeks
Maraviroc plus atazanavir/ritonavir in a nuke-sparing regimen in treatment-naive patients
Five-year results from raltegravir registrational studies
First report: atazanavir-related gallstones (cholelithiasis)
Paediatrics studies at 19th International AIDS Conference and the 4th International Workshop on HIV Pediatrics
Novel lopinavir/ritonavir sprinkle formulation for children in resource-limited settings
Update on new antiretrovirals for children and adolescents
Tenofovir prophylaxis for neonates
Efavirenz levels variable in children in the CHAPAS-3 study
Early initiation of ART is associated with growth recovery in children in NEVEREST-2
High prevalence of peripheral neuropathy in children taking d4T in rural South Africa
Lipid profile in children in PREDICT: immediate versus deferred nevirapine-based ART
High levels of maraviroc in rectal tissue fail to protect macaques from SIV transmission following rectal exposure
Mechanisms for circumcision to reduce HIV transmission in different penile tissue: target cell differences rather than keratinisation
Towards an HIV cure: early developments reported
Important publications launched at IAS 2012
14th International Workshop on Co-morbidities and Adverse Drug Reactions (IWCADR), 19–21 July 2012, Washington
Skeletal muscle toxicity and raltegravir
Proteinuria as a potential early marker of tenofovir-related renal toxicity
Earlier and greater comorbidities reported in HIV positive cohort
20th International HIV Drug Resistance Workshop, 9–13 June 2012, Sitges
In vitro resistance profile for BMS 986001
Recombination dynamics in case of MDR sub-type D following superinfection with wild-type sub-type B
Defective viral reservoir populations is common in patients on long-term suppressed ART
First case report of transmission with five-class resistance
New data on the Berlin patient: interpret with caution
Antiretrovirals
Dolutegravir indicates superiority compared to efavirenz in treatment-naïve patients: top-line results only
FDA update to darunavir label: severe skin reactions
Treatment access
FDA approval of generic ARVs
Activists protest at IAS for Global Fund to stick to principles
EU parliament rejects anti-counterfeiting trade agreement: allows continued access to generic medicines
US trade deal threatens access to medicines
Side effects
Theratechnologies withdraw EU application for tesamorelin (Egrifta)
Recent studies on HIV, ART and osteoporotic fracture risk
HIV prevention and transmission
FDA approve Truvada to reduce the risk of sexual transmission
Basic science and immunology
Role of cell-to-cell transmission in sustaining the HIV reservoir
Book and film reviews
ACT-UP in film: ‘How to survive a plague’ and ‘United in anger’
On the web
PLoS Medicine (July 2012)
PDFs
Volume 13 Number 7/8 July/August 2012 PDF
HTB RSS
Current issues
October 2024
September 2024
August 2024
Back issues
Special report
HIV diagnoses in England jump by 51% in 2023: missing targets and highlighting disparities in access to care
6 October 2024
More from HTB
Conference reports
Conference shortcuts
Articles by subject
PDFs
Subscribe
HTB homepage
Home
i-Base homepage